sefulness of TSPO-PET and related biomarkers in the patients with neuropathic pai

Not Applicable

• Conditions: europathic pain

• Registration Number: JPRN-UMIN000028113
• Lead Sponsor: Osaka University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-01
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Not provided

Exclusion Criteria

<Exclusion criteria for patients> 1. Pregnant women, nursing mothers and the women who may be pregnant. 2. The patients with the severe psycho-neurologic disease (major depression or schizophrenia). 3. Patients with a history of the severe injury with sliding symptoms due to a vertebral fracture and the backbone trauma within six months. 4. Patients with the discectomy, nerve cauterization, and vertebra plasty within six months. 5. Algetic patients due to articular rheumatism, ankylosing spondylitis, and spinal inflammation or tumor. 6. Patients who are unsolved accident compensation about the pain and financial mediation/suit. 7. Patients with a history of HIV. 8. Patients who are participating into other clinical trials. 9. Patients who are judged to be inadequate as subjects by the principal investigator. <Exclusion criteria for normal volunteers> 1. Pregnant women, nursing mothers and the women who may be pregnant. 2. Subjects with the severe psycho-neurologic disease (major depression or schizophrenia). 3. Subjects who suffer from hypertention, hyperlipidemia, vascular disease, and/or cardiac disease. 4. The subjects who have symptoms of pain. 5. Subjects who have claustrophobia. 6. Subjects who suffer from malignant tumors. 7. Subjects who have allergy. 8. Subjects who have smoking behavior and alcohol indulgence. 9. Subjects with a history of HIV. 10. Subjects who are participating into other clinical trials. 11. Subjects who are judged to be inadequate as subjects by the principal investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Spinal accumulations of TSPO-PET (C-11 DPA-713 PET) in the patients with neuropathic pain, which are evaluated within 4 weeks after entry. Relationships between spinal accumulation of TSPO-PET and plasma 24OHC or plasma BDNF.